tbuckley/cabot-search huggingface dataset:
Expert consensus on early orthodontic treatment of class III malocclusion
Authors: Xin Zhou, Si Chen, Chenchen Zhou, Zuolin Jin, Hong He, Yuxing Bai, Weiran Li, Jun Wang, Min Hu, Yang Cao, Yuehua Liu, Bin Yan, Jiejun Shi, Jie Guo, Zhihua Li, Wensheng Ma, Yi Liu, Huang Li, Yanqin Lu, Liling Ren, Rui Zou, Linyu Xu, Jiangtian Hu, Xiuping Wu, Shuxia Cui, Lulu Xu, Xudong Wang, Songsong Zhu, Li Hu, Qingming Tang, Jinlin Song, Bing Fang, Lili Chen
Journal: International Journal of Oral Science (2025)

Abstract The prevalence of Class III malocclusion varies among different countries and regions. The populations from Southeast Asian countries (Chinese and Malaysian) showed the highest prevalence rate of 15.8%, which can seriously affect oral function, facial appearance, and mental health. As anterior crossbite tends to worsen with growth, early orthodontic treatment can harness growth potential to normalize maxillofacial development or reduce skeletal malformation severity, thereby reducing the difficulty and shortening the treatment cycle of later-stage treatment. This is beneficial for the physical and mental growth of children. Therefore, early orthodontic treatment for Class III malocclusion is particularly important. Determining the optimal timing for early orthodontic treatment requires a comprehensive assessment of clinical manifestations, dental age, and skeletal age, and can lead to better results with less effort. Currently, standardized treatment guidelines for early orthodontic treatment of Class III malocclusion are lacking. This review provides a comprehensive summary of the etiology, clinical manifestations, classification, and early orthodontic techniques for Class III malocclusion, along with systematic discussions on selecting early treatment plans. The purpose of this expert consensus is to standardize clinical practices and improve the treatment outcomes of Class III malocclusion through early orthodontic treatment.
Expert consensus on imaging diagnosis and analysis of early correction of childhood malocclusion
Authors: Zitong Lin, Chenchen Zhou, Ziyang Hu, Zuyan Zhang, Yong Cheng, Bing Fang, Hong He, Hu Wang, Gang Li, Jun Guo, Weihua Guo, Xiaobing Li, Guangning Zheng, Zhimin Li, Donglin Zeng, Yan Liu, Yuehua Liu, Min Hu, Lunguo Xia, Jihong Zhao, Yaling Song, Huang Li, Jun Ji, Jinlin Song, Lili Chen, Tiemei Wang
Journal: International Journal of Oral Science (2025)

Abstract Early correction of childhood malocclusion is timely managing morphological, structural, and functional abnormalities at different dentomaxillofacial developmental stages. The selection of appropriate imaging examination and comprehensive radiological diagnosis and analysis play an important role in early correction of childhood malocclusion. This expert consensus is a collaborative effort by multidisciplinary experts in dentistry across the nation based on the current clinical evidence, aiming to provide general guidance on appropriate imaging examination selection, comprehensive and accurate imaging assessment for early orthodontic treatment patients.
Proton pump inhibitors are associated with occlusion of lumen-apposing metal stents and higher frequency of endoscopic necrosectomies – A European-wide multicenter cohort study
Authors: Jacob Hamm, Alzbeta Busana, Ahmad Amanzada, Alexander Arlt, Thomas Asendorf, Samantha Carswell, Ulrike Denzer, Louis Elsing, Fabian Frost, Lucía Guilabert, Karim Hamesch, Marcus Hollenbach, Péter Hegyi, Alexander Kleger, Jan Krivinka, Lumir Kunovsky, Christian Meinhardt, Veit Phillip, Sophie Schlosser-Hupf, Simon Sirtl, Lukas Welsch, Julian Cardinal von Widdern, Albrecht Neesse, Christoph Ammer-Herrmenau
Journal: Endoscopy (2025)

Background: Lumen apposing metal stents (LAMS) are widely used to drain walled-off necrosis (WON). LAMS occlusion is considered a significant clinical problem and identification of risk factors for LAMS occlusion could contribute to novel preventive strategies. A previous study suggested contradictory effects of proton pump inhibitor (PPI) intake on the occlusion and necrosectomy rate. Methods: We conducted a European-wide multicenter retrospective cohort study assessing WONs drained by LAMS. Primary aims were to assess the strength of an association between PPI intake and LAMS occlusion and necrosectomies rates. The secondary aim was to assess the strength of an association between PPI intake and other LAMS-associated complications. Multiple mixed effects models were used to control for possible confounding covariates. Results: 893 patients with 967 LAMS from 17 centers were included retrospectively. After exclusion of 10 incomplete datasets and patients who took PPIs intermittently, 768 LAMS remained. Overall occlusion rate was 27.9%. Most occlusion events occurred within 10 days. Most patients received PPIs continuously (continuous intake (cPPI) n = 577, no intake (nPPI) n = 191). In patients who did not use PPIs continuously, lower LAMS occlusion (OR 0.61, p 0.039*) and necrosectomy rates were observed (IRR 0.8, p 0.006**). A post-hoc analysis exhibited a dose- and compound-dependent effect of PPI-intake on necrosectomy rate. We did not observe any increase in other complications in the nPPI group such as bleeding events (OR 0.88, p 0.9). Conclusion: Intake of PPIs upon LAMS placement is associated with a higher LAMS occlusion and necrosectomy rate.
STAT3 Signaling Pathway in Health and Disease
Authors: Md Abdus Samad, Iftikhar Ahmad, Aakifah Hasan, Mohammad Hassan Alhashmi, Arusha Ayub, Fahad A. Al‐Abbasi, Ajoy Kumer, Shams Tabrez
Journal: MedComm (2025)

ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor involved in multiple physiological and pathological processes. While STAT3 plays an essential role in homeostasis, its persistent activation has been implicated in the pathogenesis of various diseases, particularly cancer, bone‐related diseases, autoimmune disorders, inflammatory diseases, cardiovascular diseases, and neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis is central to STAT3 activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, and therapy resistance. Despite extensive research, the precise mechanisms underlying dysregulated STAT3 signaling in disease progression remain incompletely understood, and no United States Food and Drug Administration (USFDA)‐approved direct STAT3 inhibitors currently exist. This review provides a comprehensive evaluation of STAT3's role in health and disease, emphasizing its involvement in cancer stem cell maintenance, metastasis, inflammation, and drug resistance. We systematically discuss therapeutic strategies, including JAK inhibitors (tofacitinib, ruxolitinib), Src Homology 2 domain inhibitors (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), and nanomedicine‐based drug delivery systems, which enhance specificity and bioavailability while reducing toxicity. By integrating molecular mechanisms, disease pathology, and emerging therapeutic interventions, this review fills a critical knowledge gap in STAT3‐targeted therapy. Our insights into STAT3 signaling crosstalk, epigenetic regulation, and resistance mechanisms offer a foundation for developing next‐generation STAT3 inhibitors with greater clinical efficacy and translational potential.
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis
Authors: Pawan Kumar, Arti Yadav, Samip N. Patel, Mozaffarul Islam, Quintin Pan, Sofia D. Merajver, Theodoros N. Teknos
Journal: Molecular Cancer (2025)
Macrophage ATF6 accelerates corticotomy-assisted orthodontic tooth movement through promoting Tnfα transcription
Authors: Zhichun Jin, Hao Xu, Weiye Zhao, Kejia Zhang, Shengnan Wu, Chuanjun Shu, Linlin Zhu, Yan Wang, Lin Wang, Hanwen Zhang, Bin Yan
Journal: International Journal of Oral Science (2025)

Abstract Corticotomy is a clinical procedure to accelerate orthodontic tooth movement characterized by the regional acceleratory phenomenon (RAP). Despite its therapeutic effects, the surgical risk and unclear mechanism hamper the clinical application. Numerous evidences support macrophages as the key immune cells during bone remodeling. Our study discovered that the monocyte-derived macrophages primarily exhibited a pro-inflammatory phenotype that dominated bone remodeling in corticotomy by CX3CR1 CreERT2 ; R26 GFP lineage tracing system. Fluorescence staining, flow cytometry analysis, and western blot determined the significantly enhanced expression of binding immunoglobulin protein (BiP) and emphasized the activation of sensor activating transcription factor 6 (ATF6) in macrophages. Then, we verified that macrophage specific ATF6 deletion (ATF6 f/f ; CX3CR1 CreERT2 mice) decreased the proportion of pro-inflammatory macrophages and therefore blocked the acceleration effect of corticotomy. In contrast, macrophage ATF6 overexpression exaggerated the acceleration of orthodontic tooth movement. In vitro experiments also proved that higher proportion of pro-inflammatory macrophages was positively correlated with higher expression of ATF6. At the mechanism level, RNA-seq and CUT&amp;Tag analysis demonstrated that ATF6 modulated the macrophage-orchestrated inflammation through interacting with Tnfα promotor and augmenting its transcription. Additionally, molecular docking simulation and dual-luciferase reporter system indicated the possible binding sites outside of the traditional endoplasmic reticulum-stress response element (ERSE). Taken together, ATF6 may aggravate orthodontic bone remodeling by promoting Tnfα transcription in macrophages, suggesting that ATF6 may represent a promising therapeutic target for non-invasive accelerated orthodontics.
High-resolution Automated Free-Breathing Coronary Magnetic Resonance Angiography in Comparison to Coronary Computed Tomography Angiography
Authors: Gregory Wood, Alexandra Uglebjerg Pedersen, Bjarne Linde Nørgaard, Christian Alcaraz Frederiksen, Jesper Møller Jensen, Karl-Philipp Kunze, Radhouene Neji, Jens Wetzl, Claudia Prieto, René M Botnar, Won Yong Kim
Journal:  (2025)

Abstract Background Clinical implementation of coronary magnetic resonance angiography (CMRA) is limited due to variability in image quality. A protocol utilizing an image navigator (iNAV) integrated with automated scan planning has been developed to facilitate consistent diagnostic image quality. Objectives To evaluate the agreement of automated iNAV CMRA compared with Coronary CT angiography (CCTA) using Coronary Artery Disease Reporting and Data System (CAD-RADS) to classify Coronary Artery Disease (CAD). Methods 95 Individuals underwent automated iNAV CMRA at a resolution of 0.7 mm3 with a Deep-learning assisted automated scan planning and trigger-delay detection protocol. CMRA and CCTA datasets were analysed using CAD-RADS to classify the per-patient severity of CAD. Additionally, the accuracy of both imaging modalities in predicting referral for invasive coronary angiography (ICA) and coronary revascularisation was assessed. Results CMRA classification for CAD-RADS ≥1, ≥2, ≥3 and ≥4 agreed with CCTA for 80%, 73%, 63% and 70% of cases respectively. The area under the receiver-operating characteristic curves with CAD-RADS ≥4 and ≥ 3 for CMRA and CCTA were comparable in predicting ICA referral (0.75 vs. 0.70, p = 0.687 and 0.70 vs. 0.70, p = 0.945) and revascularisation (0.72 vs. 0.74, p = 0.811 and 0.68 vs. 0.76, p = 0.089). Conclusions A novel automated iNAV CMRA protocol was implemented, investigating individuals at risk of CAD. Using the CAD-RADS classification there was moderate to good agreement between CMRA and CCTA. In patients with CAD-RADS ≥4 and ≥ 3, CMRA was as effective as CCTA in predicting ICA referral and revascularisation.
Sound Wave‐Activated Self‐Powered Adhesive Dressing for Accelerated Wound Healing
Authors: Shuo‐bing Yang, Zheng‐dong Yuan, Bai‐yang Yu, Tong‐tong Wang, Wei Wang, Ting Li, Yang Wang, Jing Huang, Feng‐lai Yuan, Wei‐fu Dong
Journal: Advanced Healthcare Materials (2025)

Abstract Self‐powered wound dressings are effective in treating chronic wounds because of their low toxicity and convenience. However, current self‐powered dressings rely on the bending movements of the skin or additional large ultrasonic devices. Herein, a flexible adhesive self‐powered wound dressing (FASW) that promotes skin regeneration through daily sound wave driving without relying on skin bending or external sound devices is proposed. The FASW dressing consists of a bioadhesive film (BAF), a unidirectional fluorinated conductive film (UFCF), and a liquid metal (LM) interlayer. Benefiting from the cross‐linking of chitosan, the dressing exhibits excellent properties, such as biocompatibility, stretchability, tissue adhesion, and recyclability. In vivo experiments show that the FASW dressing reduced inflammation and stimulated hair follicle regeneration. This wound dressing utilizes previously overlooked natural energies for the treatment of chronic wounds, thereby enhancing the therapeutic effect of traditional self‐powered dressings on individuals with movement disorders.
Leveraging the Shape Fidelity of 3D Printed Bone Scaffolds Through Architectural Tailoring of an Emulsion Ink: A Combined Experimental and Computational Analysis
Authors: Sagnik Ghosh, Shubham Shankar Mohol, Anupama Datta, Pulak Mohan Pandey, Ritu Kulshreshtha, Bhanu Nandan, Minna Hakkarainen, Rajiv K. Srivastava
Journal: Advanced Healthcare Materials (2025)

Abstract Hierarchical porous, bioactive, and biocompatible scaffolds with customizable multi‐functionality are promising alternatives for autografts and allografts in bone tissue engineering. Combining high internal phase emulsion (HIPE) templating with additive manufacturing provides possibilities to produce such multiscale porous scaffolds. 3D printing of HIPE remains a challenging task due to the intense phase separation under high shear extrusion and reported printability (P r ) of either less than or greater than 1. Tuning viscoelastic properties of emulsion is therefore required to achieve a P r ≈1. This study addresses these issues by preparing Pickering HIPEs using dual networks with synergistic viscous and elastic properties, stabilized by Cloisite 30B interphase. This configuration enhances viscoelasticity and achieves P r values close to 1 (0.98–1.02). The printed scaffolds exhibit trabecular bone‐like, hierarchical interconnected porosity (77%–86%). Computational simulations accurately predict the mechanical, biological, and degradation behavior. Functionalization with Cissus quadrangularis bioactivates the scaffolds, demonstrates in vivo biocompatibility, promotes MC3T3‐E1 adhesion, and proliferation, accelerates osteogenesis, and reduces oxidative stress compared to neat PCL scaffolds. This work introduces a facile strategy for “engineering printability” to produce regenerative materials with hierarchical design and holds the potential for developing optimized bone tissue engineering scaffolds.
Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score
Authors: Filipa Lynce, Samuel M Niman, Megumi Kai, Sean Ryan Ma, Elizabeth Troll, Li Li, Kathy D Miller, Reshma Jagsi, Ginny Mason, Beth A Overmoyer, H T Carisa Le-Petross, Faina Nakhlis, Savitri Krishnamurthy, Beth T Harrison, Susie X Sun, Eren D Yeh, Jennifer R Bellon, Laura E Warren, Michael C Stauder, Meredith M Regan, Wendy A Woodward
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Purpose Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to propose novel quantitative scoring rubrics for IBC diagnosis. In this study, we developed a multi-institutional clinical dataset to test and validate the proposed scoring system. Methods IBC (N = 988) and non-IBC (N = 332) cases were identified at two institutions with dedicated multidisciplinary IBC programs. The non-IBC cohort included consecutive cT4b and cT4c patients. Standard operating procedures (SOPs) were developed for all ambiguous findings and languages. Three different methods were used for the imputation of missing data, resulting in three separate datasets. The sensitivity, specificity, and area under the receiver operator characteristic curve (AUC-ROC) were used to assess the discrimination of the proposed scoring rubric. Results The distribution of “true IBC” cases was 19.7% very likely IBC, 49.1% strong possibility of IBC, 0.4% weak possibility of IBC, 0.1% very unlikely IBC, and 30.7% unknown; corresponding groupings for true non-IBC cases were 0.6% very likely IBC, 51.8% strong possibility of IBC, 9.9% weak possibility of IBC, 2.1% very unlikely IBC, and 35.5% unknown. AUC-ROC values for missing data imputation methods were similar (0.83–0.84); exploratory score refinement improved the AUC-ROC to 0.88–0.89. Conclusion Using the largest multi-institutional IBC clinical database to date, the score has been validated and is available for clinical use at https://www.komen.org/ibc-calc to assist healthcare providers and their patients in IBC diagnosis. Exploratory score refinement demonstrates the potential to increase specificity; however, any change requires separate validation.
Extended endocrine therapy use and decision making after breast cancer diagnosis
Authors: Allison W Kurian, Allison K C Furgal, Archana Radhakrishnan, Christine M Veenstra, Paul Abrahamse, Kevin C Ward, Ann S Hamilton, Timothy P Hofer, Steven J Katz, Lauren P Wallner, Sarah T Hawley
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Purpose Adjuvant endocrine therapy is recommended to extend beyond five years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision-making about extended endocrine therapy. Patients and Methods Women aged 20-79 diagnosed with stage I-II breast cancer in 2014-15 and reported to Georgia and Los Angeles County SEER registries were surveyed at seven months and again at six years post-diagnosis (N = 2,361; response rate = 60%). Women with estrogen receptor (ER) and/or progesterone receptor (PR)-positive disease were asked about their decision whether to continue therapy. Results Of 831 women, 591 had completed or were completing five years of endocrine therapy. Among those who had decided (n = 557), 46.9% decided to continue (39.4% stage I, 62.4% stage II). On multivariable analysis, factors associated with continuation for stage I were worry about recurrence (adjusted odds ratio (aOR) 3.35, 95% confidence interval (CI) 1.78-6.32); desire for most extensive treatment (aOR 2.15; CI 1.11-4.14); and primary care physician participation (aOR 4.30; CI 2.22-8.32). Side effects were inversely associated with continuation (stage I aOR 0.21: CI 0.11-0.41). Associations were similar for stage II; for stage I only, bilateral mastectomy and chemotherapy were associated with continuation. Decision to continue did not vary by race, ethnicity or demographic factors. Conclusions Nearly 40% of women with stage I breast cancer, and two-thirds with stage II, decided to extend endocrine therapy. Decision-making was influenced by patient values and varied little by stage. These results can inform physician-patient discussion about extending endocrine therapy.
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination
Authors: Katie A Greenzang, Kathleen E Montgomery, Adam DuVall, Michael E Roth, Mark Krailo, Michelle M Nuño, Lindsay Renfro, Natalie DelRocco, John Doski, Kara Kelly, Sharon M Castellino, Jennifer McNeer, Maureen M O’Brien, Damon Reed, Katherine Janeway, Pamela S Hinds, Sue Zupanec, Susan K Parsons
Journal: JNCI Journal of the National Cancer Institute (2025)

Understanding the patient experience of treatment toxicities and their impact on health-related quality of life (HRQoL) of cancer treatments requires asking patients themselves using patient-reported outcomes (PROs). Over the past twenty years, the National Institutes of Health (NIH) sponsored several tools, namely Patient-Reported Outcome Measurement Information System (PROMIS) measures and the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for precisely this purpose: to ensure valid, reliable tools to collect and detect patient-reported toxicities or adverse events and their impact on HRQoL. These PRO measures have been widely incorporated in clinical trials for adults with cancer. Yet, despite considerable work developing and validating developmentally appropriate versions of these measures for pediatric and adolescent self-report, PRO inclusion in pediatric and adolescent and young adult (AYA) clinical trials has lagged. Here we discuss optimal strategies to integrate validated PRO tools and sound analytic methodologies in clinical trials for children and AYAs with cancer, highlighting lessons learned from recent successes and ongoing experiences developing and opening cross-network trials for children and AYAs through the Children's Oncology Group (COG) for patients with classic Hodgkin lymphoma (cHL), osteosarcoma (OS), and acute lymphoblastic leukemia (ALL).
Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment
Authors: Viktoria Blumenberg, Benjamin R. Puliafito, Charlotte E Graham, Mark B. Leick, Md Raihan Chowdhury, Maxx King, Deshea L. Harris, Noopur S. Raje, Andrew R. Branagan, Andrew J. Yee, Diana D. Cirstea, Kathleen M.E. Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. Frigault
Journal: Blood (2025)
Enzymatic absorption promoters for non-invasive peptide delivery
Authors: Marilena Bohley Steiger, Angela Steinauer, Daniel Gao, David Klein Cerrejon, Hanna Krupke, Miguel Heussi, Padryk Merkl, Alexander Klipp, Michael Burger, Cristina Martin-Olmos, Jean-Christophe Leroux
Journal: Journal of Controlled Release (2025)
Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells
Authors: Kouhei Takashima, Vrinda Jethalia, Maria Sirenko, Lewis R. Silverman, Lewis Tomalin, Saul Carcamo, Dan Hasson, Eirini P Papapetrou
Journal: Blood (2025)
The crystal structure of the toxin EspC from enteropathogenic <i>Escherichia coli</i> reveals the mechanism that governs host cell entry and cytotoxicity
Authors: Akila U. Pilapitiya, Lilian Hor, Jing Pan, Lakshmi C. Wijeyewickrema, Robert N. Pike, Denisse L. Leyton, Jason J Paxman, Begoña Heras
Journal: Gut Microbes (2025)

Enteropathogenic E. coli (EPEC) is a significant cause of diarrhea, leading to high infant mortality rates. A key toxin produced by EPEC is the EspC autotransporter, which is regulated alongside genes from the locus of enterocyte effacement (LEE), which collectively result in the characteristic attaching and effacing lesions on the intestinal epithelium. In this study, we present the crystal structure of the EspC passenger domain (αEspC) revealing a toxin comprised a serine protease attached to a large β-helix with additional subdomains. Using various modified EspC expression constructs, alongside type III secretion system-mediated cell internalization assays, we dissect how the αEspC structural features enable toxin entry into the intestinal epithelium to cause cell cytotoxicity.